Mounjaro in June 2025: the key developments and what they mean

Step 1: what NICE approved and when NHS prescribing started

NICE published its appraisal of tirzepatide for weight management (TA1026) in December 2024, recommending it for adults with a BMI of 35 or above and at least one weight-related condition such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. From June 2025, NHS England activated the first cohort: adults with a BMI of 40 or above and four or more of those five conditions. That is a deliberately narrow starting point; the intention was always to widen access in stages as prescribing infrastructure caught up.

It is worth knowing what the June 2025 NHS start did not do. It did not open Mounjaro to everyone who meets the private licensed criteria. It did not guarantee fast access, even qualifying patients need to be enrolled in a supported programme through their GP practice, and GP participation under the new contract is optional, so availability varies by area. The NHS route involves multidisciplinary lifestyle support alongside the medicine, which is clinically valuable but adds layers of coordination.

The NICE appraisal of tirzepatide (TA1026) sets out the full eligibility framework, including the lower BMI thresholds (2.5 kg/m² lower) that apply for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds. Reading the recommendations chapter takes about ten minutes and answers most eligibility questions precisely.

Step 2: what private prescribing looked like through this period

Private access to Mounjaro through regulated online pharmacies continued unchanged through June 2025. The licensed criteria for private prescribing are set by the medicine's authorisation, not by NICE's NHS recommendations: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, are potentially eligible. A prescriber still makes the individual call.

For people who did not meet the NHS cohort criteria (the majority, at that stage) private prescription remained the practical route. There is no referral, no waiting list and no requirement to have four comorbidities. The clinical bar is still real: ID verification, a record of current weight, a medical history review, and an ongoing relationship with the prescribing team. Shortcuts that skip those steps are a warning sign, not a feature.

If you want to understand what that process looks like in practice, the guide to getting Mounjaro online walks through the steps in detail, including how to check that any pharmacy you approach is GPhC-registered. Separately, if you are curious about how the latest tirzepatide research in 2025 informs clinical decisions, that page covers the evidence picture including SURMOUNT-5.

Step 3: how the Eli Lilly price change in late 2025 affects the context

One development that sits close to the June 2025 period (even though it came a few months later) is worth knowing about: Eli Lilly raised Mounjaro's UK list price from 1 September 2025. The highest-dose pen moved from around £122 to around £330 in list terms, and typical private prices across providers have since ranged roughly £149 to £375 per month depending on the dose and the service. These figures are widely reported and are useful context for anyone budgeting.

What changed less visibly was the composition of what responsible providers charge for. At reputable services, the price covers a clinical consultation, the prescription, the medicine itself and delivery, not the pen alone. The treatment overview page sets out how nume structures this, including what is included in a single transparent price.

A word on the storage routine that catches some people out after a price increase makes them more attentive to every pen: Mounjaro KwikPens should be kept in the fridge, ideally toward the back of the door where temperature is most stable, until you are ready to use them. There is a limited window for room-temperature use, the Patient Information Leaflet gives the exact figure, and that is where you should check it rather than relying on any third-party source. At £300-plus per pen, nobody wants to find out it was stored incorrectly.

For a broader look at everything Mounjaro covers (mechanism, evidence, side effects and the difference between NHS and private access) the full Mounjaro guide is the place to start, and the tirzepatide overview adds the clinical-science layer.

What the June 2025 milestone did not resolve

A legitimate question at this point is: if the NHS started, why would anyone go private? The answer depends on the individual. If you meet NHS Cohort 1 criteria and your GP practice is participating, NHS access may suit you well. If you do not meet those criteria, if your practice is not yet set up, or if you would rather not wait, private prescription through a regulated pharmacy is the established alternative.

Scrutiny of online prescribing also intensified around this period, which is healthy. The MHRA has been clear that Mounjaro sold without a valid prescription or through unverified channels carries serious risks, fake pens have been seized in large quantities, including the discovery of an illicit manufacturing site producing counterfeit tirzepatide. Checking a pharmacy on the GPhC register before you buy takes under a minute and is the single most useful safety check available to a consumer. You can also read about recent discussions in community forums on Mounjaro in 2025 to see what questions people are actually asking their prescribers.

Legal and regulatory developments are also part of the 2025 story, the Mounjaro legal developments page covers what has been reported and what it means for UK patients. For questions about specific doses such as the 2.5 mg starting pen, the 2.5 mg Mounjaro page addresses the most common early-treatment queries.

If you would like to talk through your own situation, our prescribers are available seven days a week. Speak to our prescribers through a free consultation, no referral needed, reviewed the same day your answers arrive.